Now Available: Thailand Pharmaceuticals Competitive Intelligence Report Q4 2010

Nov. 23, 2010 - PRLog -- Thailand's pharmaceutical landscape is dominated by foreign manufacturers (to the tune of 75%), although the indigenous generic drug industry is relatively strong. For example, Thai pharmaceutical company The British Dispensary recently signed a deal with Chemical Company of Malaysia (CCM) for developing its manufacturing base and expanding its product range. With the MYR50mn (US$15.3mn) collaboration, the Thai company is looking to include halal-based cosmetic and healthcare products in its existing 18-brand portfolio. The two companies are capitalising on the Association of

Southeast Asian Nations (ASEAN) free trade area to expand their businesses in the region. In the meantime, Thailand's recognition of the need to introduce modern technology and meet internationally recognised GMP standards will improve local operating conditions, thus reducing barriers to trade. Domestic manufacturing standards are to be improved by the plans to introduce the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation (PIC/S) regulation, which will allow local manufacturers to increase their export potential. However, consolidation is likely under threat from rising competition and the need to improve intellectual property (IP) conditions. Some of the outstanding issues regarding IP are those regarding compulsory licences, which have been criticised by the foreign research-based industry. Nevertheless, in June 2010, the National Health Security Office (NHSO) decided to extend its compulsory licensing for development of generic versions of two HIV/AIDS drugs till their patent ends. Public Health Minister Jurin Laksanavisit said the licensing for efavirenz and lopinavir + ritonavir has been extended to lower the costs of treating patients suffering from HIV/AIDS. The patents for efavirenz and lopinavir + ritonavir are scheduled to expire on January 31 2012 and December 4 2016 respectively.

Despite the challenging operating environment, some foreign players are looking to expand their operations to Thailand. To this end, in March 2010, Latvian pharmaceutical company Olainfarm announced plans to open a representative office in Bangkok during 2010, while also expanding into Central Asian markets. BMI considers Olainfarm's continued push into foreign markets a sound strategy, considering its previous success in this area and limited domestic market potential. Presently, markets that are not in the Commonwealth of Independent States (CIS) represent only 6% of the company's turnover. During 2009, Olainfarm achieved 45 new drug registrations in 13 countries, including 'exotic' markets such as Tajikistan, Turkmenistan, Poland, Albania and Australia, while registration processes have also been launched in Romania and Vietnam.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/94335_thailand_pharmaceuticals...

Report Table of Contents:

Competitive Landscape Analysis
- Pharmaceutical Industry
- Table: Thailand - Leading Pharmaceutical Companies by Sales Revenues (2009)
Company Profiles
- Domestic Manufacturer Profiles
- Siam Pharmaceutical
- Government Pharmaceutical Organisation (GPO)
- Biolab
- Thai Meiji Pharmaceutical Company
- Berlin Pharmaceutical Industry
- Leading Multinational Manufacturers
- Pfizer
- Sanofi-Aventis
- GlaxoSmithKline
- Merck & Co
- Novartis
Market Attractiveness Analysis
- Market Overview
- Regulatory Analysis
- Regulatory Regime
- Intellectual Property Regime
- IP Shortcomings
- Counterfeit Drugs
- Compulsory Licensing Regulatory Developments
- IP Developments
- Pricing And Reimbursement
SWOT Analysis
- Thailand Pharmaceutical And Healthcare Industry SWOT
Risk/Reward Rating
- Pharmaceutical Business Environment Ratings
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q410
- Rewards
- Risks
Business Development Directory

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.